Systemic sclerosis in adults. Part I: Clinical features and pathogenesis
- PMID: 35131402
- DOI: 10.1016/j.jaad.2021.10.065
Systemic sclerosis in adults. Part I: Clinical features and pathogenesis
Abstract
Systemic sclerosis (SSc), also referred to as systemic scleroderma or scleroderma, is a rare, complex immune-mediated connective tissue disease characterized by progressive skin fibrosis and other clinically heterogenous features. The etiopathogenesis of SSc involves vasculopathy and immune system dysregulation occurring on a permissive genetic and epigenetic background, ultimately leading to fibrosis. Recent developments in our understanding of disease-specific autoantibodies and bioinformatic analyses has led to a reconsideration of the purely clinical classification of diffuse and limited cutaneous SSc subgroups. Autoantibody profiles are predictive of skin and internal organ involvement and disease course. Early diagnosis of SSc, with commencement of disease-modifying treatment, has the potential to improve patient outcomes. In SSc, many of the clinical manifestations that present early signs of disease progression and activity are cutaneous, meaning dermatologists can and should play a key role in the diagnosis and management of this significant condition. The first article in this continuing medical education series discusses the epidemiology, clinical characteristics, and pathogenesis of SSc in adults, with an emphasis on skin manifestations, the important role of dermatologists in recognizing these, and their correlation with systemic features and disease course.
Keywords: clinical features; cutaneous manifestations; differential diagnosis; disease classification; epidemiology; pathogenesis; systemic sclerosis.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Conflicts of interest Dr Jerjen has no conflicts of interest to disclose. Dr Nikpour has received research grant support from Actelion, BMS, GSK, Janssen, and UCB and honoraria from Actelion, Boehringer Ingelheim, Janssen, Eli Lilly, Pfizer, and UCB. Dr Krieg has received speaking fees from Actelion. Dr Denton reports personal fees or research grants to his institution from GlaxoSmithKline, Galapagos, Boehringer Ingelheim, Roche, CSL Behring, Corbus, Horizon, and Arxx Therapeutics outside the submitted work. Dr Saracino has received speaking fees from UCB.
Comment in
-
Reply to Letter to the Editor: Sclerosis terminology in the spotlight.J Am Acad Dermatol. 2023 Oct;89(4):e173-e174. doi: 10.1016/j.jaad.2023.06.009. Epub 2023 Jun 13. J Am Acad Dermatol. 2023. PMID: 37315801 No abstract available.
-
Response to Jerjen et al's "Systemic sclerosis in adults. Part I: clinical features and pathogenesis".J Am Acad Dermatol. 2023 Oct;89(4):e171. doi: 10.1016/j.jaad.2023.04.074. Epub 2023 Jun 13. J Am Acad Dermatol. 2023. PMID: 37315804 No abstract available.
Similar articles
-
Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.Clin Rev Allergy Immunol. 2017 Dec;53(3):306-336. doi: 10.1007/s12016-017-8625-4. Clin Rev Allergy Immunol. 2017. PMID: 28712039 Review.
-
[Mimetics of systemic sclerosis].Z Rheumatol. 2019 Feb;78(1):14-23. doi: 10.1007/s00393-018-0538-y. Z Rheumatol. 2019. PMID: 30255410 Review. German.
-
Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc).Autoimmun Rev. 2015 Mar;14(3):210-3. doi: 10.1016/j.autrev.2014.11.002. Epub 2014 Nov 18. Autoimmun Rev. 2015. PMID: 25461837 Review.
-
Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients.Arthritis Rheum. 2000 Feb;43(2):444-51. doi: 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G. Arthritis Rheum. 2000. PMID: 10693887
-
Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.Arthritis Rheumatol. 2020 Mar;72(3):465-476. doi: 10.1002/art.41153. Epub 2020 Jan 28. Arthritis Rheumatol. 2020. PMID: 31682743
Cited by
-
IFIT3 mediates TBK1 phosphorylation to promote activation of pDCs and exacerbate systemic sclerosis in mice.Clin Transl Med. 2024 Sep;14(9):e1800. doi: 10.1002/ctm2.1800. Clin Transl Med. 2024. PMID: 39305055 Free PMC article.
-
Research progress of SIRTs activator resveratrol and its derivatives in autoimmune diseases.Front Immunol. 2024 Jun 19;15:1390907. doi: 10.3389/fimmu.2024.1390907. eCollection 2024. Front Immunol. 2024. PMID: 38962006 Free PMC article. Review.
-
Malondialdehyde Serum Levels in Patients with Systemic Sclerosis Relate to Dyslipidemia and Low Ventricular Ejection Fraction.Antioxidants (Basel). 2023 Aug 25;12(9):1668. doi: 10.3390/antiox12091668. Antioxidants (Basel). 2023. PMID: 37759971 Free PMC article.
-
Non-cirrhotic Portal Hypertension as the Initial Presentation of Limited Cutaneous Scleroderma: A Case Report.J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231171251. doi: 10.1177/23247096231171251. J Investig Med High Impact Case Rep. 2023. PMID: 37132021 Free PMC article.
-
Exosomes in Systemic Autoimmune Diseases: Recent Advances in Diagnostic Biomarkers and Therapeutic Applications.Int J Nanomedicine. 2025 Apr 21;20:5137-5160. doi: 10.2147/IJN.S506221. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40292402 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical